Amendments to the Specification

Please add the following section at page 2, above line 24, before the "Description of Preferred Embodiments:"

Brief Description of the Drawings

Fig. 1 is a graph showing effects of cyclised VEGF Exon 7-derived peptides on ^{125}I-VEGF$_{165}$ binding to PAE/NP1 cells.

Fig. 2 is a series of graphs showing inhibition of ^{125}I-VEGF$_{165}$ binding to various cells.

Fig. 3 is a depiction of inhibited VEGF-induced KDR phosphorylation.

Fig. 4 is a graph showing that peptide EG3287 inhibits binding of radiolabelled VEGF to the breast carcinoma cell line MDA-MB-231.

Brief Description of the Sequences

SEQ ID NO:1 is the amino acid sequence of the shortest active cyclised VEGF Exon 7-derived peptide from isoform 165 of the human vascular endothelial growth factor polypeptide VEGF-A that is necessary for inhibition of VEGF binding to HUVECs.

SEQ ID NO:2 is the amino acid sequence of a novel cyclised VEGF Exon 7-derived peptide that has NP-1 antagonist activity according to the subject invention.

SEQ ID NO:3 is the amino acid sequence of VEGF$_{189}$ mutant 3283, cyclo VEGF$_{189}$ (152-163) from Fig. 1.

SEQ ID NO:4 is the amino acid sequence of VEGF$_{189}$ mutant 3284, cyclo VEGF$_{189}$ (154-161) from Fig. 1.

SEQ ID NO:5 is the amino acid sequence of VEGF$_{189}$ mutant 3285, cyclo VEGF$_{189}$ (152-163) from Fig. 1.

SEQ ID NO:6 is the amino acid sequence of VEGF$_{165}$ peptide 3286, dicyclo VEGF$_{165}$ (111-138) from Fig. 1.

Please amend page 13, lines 3-5 (Abstract) as follows:

A novel <u>isolated</u> peptide<u>, in bicyclic form,</u> having the amino acid sequence SCKNTDSRCKARQLELNERTCRCDKPRR <u>(SEQ ID NO:2)</u> or a fragment thereof that substantially retains N̶P̶-̶1̶ <u>neuropilin-1</u> antagonist activity, in cyclic form, is proposed for use in therapy.

Please replace existing Fig. 1 with the attached Replacement Sheet for Fig. 1. An Annotated Sheet showing changes made is attached following the Remarks section of this Amendment.

Please replace existing page 1 of the Sequence Listing with new pages 1-3, which are attached following the Replacement Sheet and Annotated Sheet for Fig. 1.